Clinical Research & Related Services
Total Trials
15
As Lead Sponsor
1
As Collaborator
14
Total Enrollment
628
NCT03179423
Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years
Phase: Phase 2
Role: Collaborator
Start: Jun 14, 2017
Completion: May 7, 2019
NCT04323306
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.
Phase: Phase 1
Start: Aug 12, 2020
Completion: Sep 27, 2022
NCT04456634
Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine
Start: Sep 10, 2020
Completion: Nov 17, 2020
NCT05114889
Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis
Start: Oct 25, 2021
Completion: Feb 15, 2023
NCT05205941
MMV533 Plasmodium Falciparum Volunteer Infection Study
Start: Mar 30, 2022
Completion: Sep 2, 2022
NCT05287893
Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria
Start: Apr 4, 2022
Completion: Sep 26, 2022
NCT05272605
Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults
Start: Apr 5, 2022
Completion: Apr 19, 2023
NCT05298306
A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain
Start: May 17, 2022
Completion: Jun 16, 2023
NCT05605470
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
Start: Jan 19, 2023
Completion: Nov 18, 2024
NCT05979207
Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
Start: Aug 1, 2023
Completion: Oct 30, 2023
NCT05809323
Marfan Syndrome Moderate Exercise Trial II
Phase: N/A
Start: Sep 1, 2023
Completion: Jul 1, 2027
NCT05994664
Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients
Start: Apr 1, 2024
Completion: Jan 1, 2028
NCT06263270
Evaluation of CYT-108, a Recombinant Protease Inhibitor, for Treatment of Mild to Moderate Primary Osteoarthritis of the Knee
Start: Jun 1, 2024
Completion: Dec 31, 2024
NCT06891729
Plan A Novel Delivery Device Study
Start: Mar 15, 2025
Completion: Jul 6, 2025
NCT06933043
A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults.
Role: Lead Sponsor
Start: May 20, 2025
Completion: Nov 8, 2025
Loading map...